TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06360900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Electrical transcutaneous auricular vagus nerve stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: taVNS
Description: Electrical transcutaneous auricular vagus nerve stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: Education of FD condition

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education Control
Description: Education of FD condition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham taVNS
Description: Sham (no current) transcutaneous auricular vagus nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham taVNS
Description: Sham (no current) transcutaneous auricular vagus nerve stimulation
Study: NCT05610605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health intervention programme: FRAGSALUD
Description: The FRAGSALUD Program consists in two parts, a first part of health education that will be taught in a group in four sessions, and a second part of individual treatment and follow-up, individual consultations will have a bimonthly periodicity until reaching one year, at which time that the program ends and a final evaluation will be carried out to assess whether the changes are maintained 15 months after the start.
Study: NCT05175456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bedjet
Description: Bedjet is a sleep cooling system. All participants will be provided a Bedjet system as part of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Each participant will receive a FitBit device to track sleep quality and related information.
Study: NCT05692466

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive molecular panel test
Description: Lab test

Intervention type: OTHER
Intervention: EORTC QLQ-30
Description: Quality of life questionnaire
Study: NCT05544851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups.
Study: NCT04650607

Intervention type: OTHER
Intervention: Adverse event after injection of phages
Description: rate and description of adverse event after injection of phages

Intervention type: OTHER
Intervention: Adverse event after injection of phages
Description: rate and description of adverse event after injection of phages
Study: NCT05907395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral suspension given in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral suspension given in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral suspension given in each cohort.
Study: NCT04918615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.
Study: NCT06527053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: obturator
Description: special maxillofacial device to close hollow defects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: obturator
Description: special maxillofacial device to close hollow defects
Study: NCT06279897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Surface Rewarming
Description: Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~90°F and held here for the duration of the LBNP test.
Study: NCT06470932

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow-up consult
Description: Patients will be ask to participate to a follow-up consult
Study: NCT05226663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo \[18F\]FFT PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluorthanatrace
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo \[18F\]FFT PET/CT
Study: NCT05555888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Shor-course radiotherapy: 25Gy/5Fx
Study: NCT06429020

Intervention type: BIOLOGICAL
Intervention: the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.
Description: record the condition of vaccination
Study: NCT05880992

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Aerobic and Strength exercises (equipment free, simple, modifiable)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Aerobic and Strength exercises (equipment free, simple, modifiable)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutrition
Description: Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutrition
Description: Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: Deep (box) breathing completing in the morning, evening and as needed.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: Deep (box) breathing completing in the morning, evening and as needed.
Study: NCT06027268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: IV infusion Day 1 and Day 8 every 21 days, at dose of 240 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion Day 1 every 21 days, at dose of 200 mg
Study: NCT06279897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Surface Warming
Description: Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~93°F and held here for the duration of the LBNP test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Surface Heating
Description: Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~95°F and held here for the duration of the LBNP test.
Study: NCT06027268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion Day 1 and Day 8 every 21 days, at dose 1000 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Day 1 and Day 8 every 21 days, at dose area under curve (AUC) 2 (maximum of 300 mg)
Study: NCT06279897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Surface Cooling
Description: Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will remain lowered to \~82°F for the duration of the LBNP test.
Study: NCT06362876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Counseling Based on Motivational Interviewing
Description: Breastfeeding Counseling Based on Motivational Interviewing Program The breastfeeding counseling based on motivational interviewing program consists of 6 sessions and 4 hours. It includes information about breastfeeding, motivational preparation for the breastfeeding experience.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Breastfeeding Consultancy
Description: Standart Breastfeeding Consultancy The standard breastfeeding consultancy program consists of 6session and 4 hours. It contains only information and applications about breastfeeding
Study: NCT05842083

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: On-site supportive communication training
Description: On-site supportive communication training
Study: NCT06307808

Intervention type: DRUG
Intervention: Tacrolimus
Description: Immunosuppressive drug: main immunosuppressant is a calcineurin inhibitor (CNI), namely tacrolimus

Intervention type: DRUG
Intervention: Tacrolimus
Description: Immunosuppressive drug: main immunosuppressant is a calcineurin inhibitor (CNI), namely tacrolimus

Intervention type: DRUG
Intervention: Belatacept
Description: Immunosuppressive drug: main immunosuppressant is a costimulation inhibitor, namely belatacept
Study: NCT05474612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiology taping with conventional therapy
Description: Two pieces of the tape cutted in a Y-shape. Applied on deep cervical extensors and upper fibers of trapezius. Length of the tape may vary from person to person. Patient is instructed to keep the tape for at-least 2 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument assisted soft tissue mobilization with conventional therapy
Description: IASTM using tools over the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants are in a comfortable position during treatment.
Study: NCT05624359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FA plus ropivacaine
Description: Th group will receive 0.17% FA and 0.5% ropivacaine for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine alone
Description: The ropivacaine alone group will receive 0.5% ropivacaine alone for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
Study: NCT05354245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre supplement (potato-pectin)
Description: Fibre supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-protein diet
Description: High-protein diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High-protein diet
Description: High-protein diet
Study: NCT04370145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulperazon
Description: moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Description: severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem Injection
Description: cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
Study: NCT05953285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative.
Study: NCT02880163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ResQFoam
Description: Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma
Study: NCT05798403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all needles will be lifting, twirling, and thrusting to reach de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.~An electrical stimulator is applied to ipsilateral BL32 and BL35 (KI12 and ST28) with continuous waves of 30 Hz and currents of 1 to 5.0 mA. During the study, oral Solifenacin Succinate placebo will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate Tablets
Description: During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needlesbeing pulled out.
Study: NCT05911347

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: 15g psyllium added to inulin solution to form a gel

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylcellulose
Description: 15 g methylcellulose added to inulin solution to form a gel

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 15g maltodextrin added to inulin solution to form a gel
Study: NCT06417957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cultural competence training
Description: The peer students in the experimental group will be given a total of 16 hours of cultural competence training, two days a week, two lessons per day (60 min. + 60 min.) for four weeks.
Study: NCT05881265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide+venetoclax
Description: Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
Study: NCT05843838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypotension during spinal anesthesia for cesarean section
Description: Hypotension, Mean Arterial Pressure\<65 mmHg, or Systolic arterial pressure \< 30% will be considered an initial value

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mini-mental test
Description: A Mini-Mental State test is a set of questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory).~At the end of the research, the mental test scores of the two groups will be compared and the effect of hypotension will be evaluated.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Mini-mental test
Description: A Mini-Mental State test is a set of questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory).~At the end of the research, the mental test scores of the two groups will be compared and the effect of hypotension will be evaluated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: It is a neuraxial anesthesia technique in which local anesthetic is placed directly in the intrathecal space. Spinal anesthesia will be applied to both groups with heavy bupivacaine in usual doses.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal anesthesia
Description: It is a neuraxial anesthesia technique in which local anesthetic is placed directly in the intrathecal space. Spinal anesthesia will be applied to both groups with heavy bupivacaine in usual doses.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The Bromage scale
Description: The Bromage scale is the accepted tool for motor block examination. The classification of these scores~1. complete block: unable to move feet or knees~2. almost complete: able to move feet only~3. partial: just able to flex knees; free movement of feet~4. no block: full movement of knees and feet

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: The Bromage scale
Description: The Bromage scale is the accepted tool for motor block examination. The classification of these scores~1. complete block: unable to move feet or knees~2. almost complete: able to move feet only~3. partial: just able to flex knees; free movement of feet~4. no block: full movement of knees and feet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heavy Bupivacaine for spinal anesthesia
Description: Routine clinical heavy bupivacaine doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heavy Bupivacaine for spinal anesthesia
Description: Routine clinical heavy bupivacaine doses
Study: NCT06316947

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CHW-delivered intervention
Description: WellShare CHWs will then deliver the brief, approximately 15-minute intervention to the participating parent. The new intervention components will build off existing tobacco education outreach using verbal instruction and images developed by WellShare CHWs and layer in home smoke-free rules, potential biomarker feedback about smoke exposure, and other educational intervention components that align. Additionally there will be pre and post-intervention surveys and urine samples collection for cotinine levels.
Study: NCT03896516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive Placebo orally twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive Placebo orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01
Description: GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLWL-01
Description: GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.
Study: NCT05382780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The breather respiratory muscle trainer
Description: The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic and localized breathing exercises
Description: A. Diaphragmatic breathing exercises:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~B. Localized Breathing:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~C. Mild Interval training exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interval aerobic training and respiratory training
Description: mild intensity interval aerobic training and respiratory training on treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interval aerobic training and respiratory training
Description: mild intensity interval aerobic training and respiratory training on treadmill
Study: NCT05341661

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Butterfly Prostatic Retraction Device
Description: Implantation of the Butterfly device

Intervention type: DEVICE
Group type: OTHER
Intervention: Butterfly Prostatic Retraction Device
Description: Implantation of the Butterfly device
Study: NCT05844683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate solution
Description: Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual baths
Description: Bathing will be performed at least daily using shampoo and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)